View ValuationAdhera Therapeutics 将来の成長Future 基準チェック /06現在、 Adhera Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 19Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive OfficerOn January 12, 2024, Adhera Therapeutics, Inc. received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.お知らせ • Jan 18Adhera Therapeutics, Inc. Announces Board ResignationsOn January 9, 2024, Adhera Therapeutics, Inc. received notice from Trond K. Waerness that he was resigning from Board of Directors effective January 12, 2024. Mr. Waerness’ decision to resign as director was not the result of any disagreement with the company on any matter relating to the Company’s operations, policies, or practices. Further, on January 12, 2024, the company received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the Company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.お知らせ • Nov 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 26Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesAdhera Therapeutics, Inc. announced that the company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (ADI) at the University of Alberta (U of A), located in Edmonton, Alberta, Canada. The company and U of A are finalizing the details of the trial, which are expected to be released shortly. The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes. It is anticipated that the ADI will also participate in the multi-center study. MLR-1023, a lyn kinase activator with potent beta cell proliferation activity, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 Diabetes where the Company can benefit from several factors, including the existing safety profile, which is expected to undergird the drug candidate moving directly into Phase 2 clinical trials and a shorter and less expensive clinical pathway compared to Type 2 Diabetes. Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models. There is a large addressable market due to the lack of alternative treatment options in Type 1 Diabetes aside from insulin injections or an insulin pump. In Type 1 Diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and a resulting dependency on exogenous insulin. Approximately 20%-30% of Type 1 Diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Adhera, alongside independent researchers, hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement. In addition to the U of A trial, the company is pleased to inform shareholders that progress is being made towards filing an application to uplist to the NASDAQ, a milestone that should yield additional liquidity and allow the Company to secure financing for clinical trials for both MLR-1019 for Parkinson’s Disease and MLR-1023 for Type 1 Diabetes.お知らせ • Sep 10+ 1 more updateAdhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022Adhera Therapeutics, Inc. appointed Zahed Subhan as the Company’s Chief Executive Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as the Company’s Chief Executive Officer until September 30, 2022. Mr. Subhan, 64, has been serving as the Company’s director since November 5, 2021. He has served as the Chief Executive Officer and director of Aestas Pharma Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc. (“Eppin”) since 2013, and the Chief Executive Officer of Eppin from 2013 to 2018. Mr. Kucharchuk, 41, has served as the Chairman of Board and Chief Executive Officer since July 7, 2020. He has also served on the Board of Directors of Theralink Technologies, Inc. since 2020 after previously serving in such role from September 2015 to March 2017. Previously, he served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020, and as Chief Financial Officer of Theralink from 2009 to September 2015. Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.お知らせ • Jul 20Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.お知らせ • Jun 29Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect four directors for a one-year term expiring at the next annual meeting of stockholders; to ratify the selection of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to approve amendment(s) to the Company's Certificate of Incorporation to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, par value USD 0.006 per share, at a ratio to be determined in the discretion of the Company's Board of Directors within a range of one-for-two through one-for-200, provided that in no event shall such amendments collectively exceed a reverse stock split ratio of one-for-200; and to consider other matters.お知らせ • May 20+ 1 more updateAdhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 DiabetesAdhera Therapeutics, Inc. announced that it is planning to initiate a Phase 2 clinical trial of MLR-1023 as anew treatment for Type 1 Diabetes where its role in pancreatic beta cell protection and proliferation represents a potential major breakthrough in diabetes care. MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. The active pharmaceutical ingredient (API) for this trial has already been manufactured. The Company is also actively working to initiate a Phase 2a study to evaluate MLR-1019 for Parkinson’s Disease. To the best of the Company’s knowledge, MLR-1019 is the only drug in development that has the potential to address both movement and non-movement aspects of the disease. The trial is designed to enroll Parkinson’s Disease patients with L-DOPA induced dyskinesia, a frequent and potential disabling motor side effect of levodopa therapy. The API for this trial has now entered the manufacturing process.お知らせ • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2022, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 24Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 22, 2021. According to SEC filing, Company is in financial distress due to substantial unpaid debt. Adhera Therapeutics is continuing to work with its advisors to restructure the company and to identify potential strategic transactions, including the Melior transaction to enhance the value of the company. Because of the substantial unpaid debt, if the company does not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.お知らせ • Sep 15Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsAdhera Therapeutics, Inc. provided shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes. Adhera will develop MLR-1019 as a new class of drug for PD and, to the best of the Company’s knowledge, as the only drug candidate designed to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. Based upon previous work conducted by licensing partner Melior Pharmaceuticals II, LLC (“Melior 2”), a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b clinical trials in patients with Type 2 diabetes. The Company will work under the IND of license partner Melior Pharmaceuticals I, Inc. (“Melior 1”) to continue clinical development of MLR-1023, with a transition to Type 1 diabetes as the target indication. The decision to focus on Type 1 diabetes was supported by multiple factors, including: Compelling work by an independent investigator in Canada demonstrating the ability of MLR-1023 to confer unique benefits to pancreatic beta cell (insulin producing cells) in models of Type 1 diabetes. Longer period of market exclusivity for Type 1 diabetes compared to Type 2 diabetes. Blue sky opportunity for an oral Type 1 diabetes drug (market for oral Type 2 diabetes drugs is already crowded). Cost to market is substantially lower for Type 1 diabetes compared to Type 2 diabetes.お知らせ • Aug 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 25Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of May 24, 2021. According to SEC filing, Company said that its has been working with its advisors to restructure the company with all the resources available. Adhera is identifying potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to the company or at all. If Adhera do not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.お知らせ • May 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 19Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 18, 2020. According to SEC filing, Company said that it has been working with its advisors to restructure the company and to identify potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.お知らせ • Nov 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 17Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive OfficerOn July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020.お知らせ • Jul 07Adhera Therapeutics, Inc. May File for BankruptcyAdhera Therapeutics, Inc. may file for bankruptcy, as of July 6, 2020. The company may file for bankruptcy if it fails to get the required financing. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Adhera Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ATRX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2023N/A-5-1-1N/A6/30/2023N/A-3-1-1N/A3/31/2023N/A-3-2-2N/A12/31/2022N/A-3-1-1N/A9/30/2022N/A-4-2-2N/A6/30/2022N/A-7-1-1N/A3/31/2022N/A-8-1-1N/A12/31/2021N/A-8-1-1N/A9/30/2021N/A-700N/A6/30/2021N/A-400N/A3/31/2021N/A-400N/A12/31/2020N/A-5-1-1N/A9/30/20200-9-3-3N/A6/30/20200-11-6-6N/A3/31/20200-13-7-7N/A12/31/20190-13-9-9N/A9/30/20190-12-9-9N/A6/30/20190-18-9-9N/A3/31/20190-19-12-12N/A12/31/20180-18-10-10N/A9/30/20180-17-7-7N/A6/30/2018N/A-10-4-4N/A3/31/2018N/A-6-1-1N/A12/31/2017N/A-6-2-1N/A9/30/2017N/A-4-2-1N/A6/30/2017N/A-3N/A-1N/A3/31/2017N/A-2N/A-1N/A12/31/2016N/A-1N/A-1N/A9/30/2016N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ATRXの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ATRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ATRXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ATRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ATRXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ATRXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 23:03終値2026/03/30 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Adhera Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 19Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive OfficerOn January 12, 2024, Adhera Therapeutics, Inc. received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
お知らせ • Jan 18Adhera Therapeutics, Inc. Announces Board ResignationsOn January 9, 2024, Adhera Therapeutics, Inc. received notice from Trond K. Waerness that he was resigning from Board of Directors effective January 12, 2024. Mr. Waerness’ decision to resign as director was not the result of any disagreement with the company on any matter relating to the Company’s operations, policies, or practices. Further, on January 12, 2024, the company received notice from Zahed Subhan that he was resigning as the company’s Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Subhan’s decision to resign as Chief Executive Officer and member of the Company’s Board of Directors was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
お知らせ • Nov 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/15/2023, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 26Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesAdhera Therapeutics, Inc. announced that the company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (ADI) at the University of Alberta (U of A), located in Edmonton, Alberta, Canada. The company and U of A are finalizing the details of the trial, which are expected to be released shortly. The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes. It is anticipated that the ADI will also participate in the multi-center study. MLR-1023, a lyn kinase activator with potent beta cell proliferation activity, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 Diabetes where the Company can benefit from several factors, including the existing safety profile, which is expected to undergird the drug candidate moving directly into Phase 2 clinical trials and a shorter and less expensive clinical pathway compared to Type 2 Diabetes. Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models. There is a large addressable market due to the lack of alternative treatment options in Type 1 Diabetes aside from insulin injections or an insulin pump. In Type 1 Diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and a resulting dependency on exogenous insulin. Approximately 20%-30% of Type 1 Diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Adhera, alongside independent researchers, hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement. In addition to the U of A trial, the company is pleased to inform shareholders that progress is being made towards filing an application to uplist to the NASDAQ, a milestone that should yield additional liquidity and allow the Company to secure financing for clinical trials for both MLR-1019 for Parkinson’s Disease and MLR-1023 for Type 1 Diabetes.
お知らせ • Sep 10+ 1 more updateAdhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022Adhera Therapeutics, Inc. appointed Zahed Subhan as the Company’s Chief Executive Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as the Company’s Chief Executive Officer until September 30, 2022. Mr. Subhan, 64, has been serving as the Company’s director since November 5, 2021. He has served as the Chief Executive Officer and director of Aestas Pharma Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc. (“Eppin”) since 2013, and the Chief Executive Officer of Eppin from 2013 to 2018. Mr. Kucharchuk, 41, has served as the Chairman of Board and Chief Executive Officer since July 7, 2020. He has also served on the Board of Directors of Theralink Technologies, Inc. since 2020 after previously serving in such role from September 2015 to March 2017. Previously, he served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020, and as Chief Financial Officer of Theralink from 2009 to September 2015. Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.
お知らせ • Jul 20Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.Adhera Therapeutics, Inc. (OTCPK:ATRX) enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group on July 19, 2022. While best efforts are anticipated to advance the Heads of Terms agreement to an executed definitive agreement pursuant to which Adhera will acquire PGT, no assurances of such a development are expressed, implied, or guaranteed.
お知らせ • Jun 29Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022Adhera Therapeutics, Inc., Annual General Meeting, Aug 18, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect four directors for a one-year term expiring at the next annual meeting of stockholders; to ratify the selection of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2022; to approve amendment(s) to the Company's Certificate of Incorporation to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, par value USD 0.006 per share, at a ratio to be determined in the discretion of the Company's Board of Directors within a range of one-for-two through one-for-200, provided that in no event shall such amendments collectively exceed a reverse stock split ratio of one-for-200; and to consider other matters.
お知らせ • May 20+ 1 more updateAdhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 DiabetesAdhera Therapeutics, Inc. announced that it is planning to initiate a Phase 2 clinical trial of MLR-1023 as anew treatment for Type 1 Diabetes where its role in pancreatic beta cell protection and proliferation represents a potential major breakthrough in diabetes care. MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. The active pharmaceutical ingredient (API) for this trial has already been manufactured. The Company is also actively working to initiate a Phase 2a study to evaluate MLR-1019 for Parkinson’s Disease. To the best of the Company’s knowledge, MLR-1019 is the only drug in development that has the potential to address both movement and non-movement aspects of the disease. The trial is designed to enroll Parkinson’s Disease patients with L-DOPA induced dyskinesia, a frequent and potential disabling motor side effect of levodopa therapy. The API for this trial has now entered the manufacturing process.
お知らせ • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2022, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 24Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 22, 2021. According to SEC filing, Company is in financial distress due to substantial unpaid debt. Adhera Therapeutics is continuing to work with its advisors to restructure the company and to identify potential strategic transactions, including the Melior transaction to enhance the value of the company. Because of the substantial unpaid debt, if the company does not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.
お知らせ • Sep 15Adhera Therapeutics, Inc. Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsAdhera Therapeutics, Inc. provided shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes. Adhera will develop MLR-1019 as a new class of drug for PD and, to the best of the Company’s knowledge, as the only drug candidate designed to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. Based upon previous work conducted by licensing partner Melior Pharmaceuticals II, LLC (“Melior 2”), a clear understanding of MLR-1019’s mechanism of action, abundant pre-clinical research and decades of clinical data on mesocarb, which is chemically related to armesocarb, Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b clinical trials in patients with Type 2 diabetes. The Company will work under the IND of license partner Melior Pharmaceuticals I, Inc. (“Melior 1”) to continue clinical development of MLR-1023, with a transition to Type 1 diabetes as the target indication. The decision to focus on Type 1 diabetes was supported by multiple factors, including: Compelling work by an independent investigator in Canada demonstrating the ability of MLR-1023 to confer unique benefits to pancreatic beta cell (insulin producing cells) in models of Type 1 diabetes. Longer period of market exclusivity for Type 1 diabetes compared to Type 2 diabetes. Blue sky opportunity for an oral Type 1 diabetes drug (market for oral Type 2 diabetes drugs is already crowded). Cost to market is substantially lower for Type 1 diabetes compared to Type 2 diabetes.
お知らせ • Aug 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 25Adhera Therapeutics, Inc. Contemplates Bankruptcy Adhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of May 24, 2021. According to SEC filing, Company said that its has been working with its advisors to restructure the company with all the resources available. Adhera is identifying potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to the company or at all. If Adhera do not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.
お知らせ • May 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Adhera Therapeutics, Inc. announced delayed annual 10-K filingOn 04/01/2021, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 19Adhera Therapeutics, Inc. Contemplates BankruptcyAdhera Therapeutics, Inc. is contemplating filing for bankruptcy, as of November 18, 2020. According to SEC filing, Company said that it has been working with its advisors to restructure the company and to identify potential strategic transactions to enhance the value of the company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to legacy RNA interference programs, as well as business combination transactions with operating companies. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.
お知らせ • Nov 18Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Adhera Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Adhera Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 17Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive OfficerOn July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020.
お知らせ • Jul 07Adhera Therapeutics, Inc. May File for BankruptcyAdhera Therapeutics, Inc. may file for bankruptcy, as of July 6, 2020. The company may file for bankruptcy if it fails to get the required financing.